E. Elinder

97O PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels

J. Bjöhle, A. Bosch, Y. Brandberg, 2020 .

Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?

J. Bergh, J. Bjöhle, A. Bosch, 2019, Journal of Clinical Oncology.

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.

J. Bergh, J. Hartman, J. Bjöhle, 2021, JAMA oncology.

Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015–000658-39)

L. Sharp, M. Nilsson, B. Andersson, 2023, AntiCancer Research.

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial

H. Johansson, T. Hatschek, H. Lindman, 2024, Breast cancer research and treatment.